The antihypertensive medicine market in South Korea stood at 60.3 million USD PPP in 2023. Forecasted sales from 2024 to 2028 show a steady annual increase: 62.5 million in 2024, 64.6 million in 2025, 66.3 million in 2026, 67.7 million in 2027, and 68.8 million in 2028. This represents a continuous year-on-year incremental growth, averaging to an annual CAGR of 3.35% over this forecast period.
Watch for future trends including:
- Technological advancements in drug formulations and delivery.
- Government policies and their effects on market dynamics.
- Increased prevalence of hypertension due to aging population.
